House Attorney General Jim Jordan Summons Dr. Philip Domitzer

House Attorney General Jim Jordan has called Dr. Philip Domitzer to testify following his earlier refusal to appear regarding a probe into the delays of the 2020 vaccine rollout.

Domitzer, who formerly headed global vaccine research and development at Pfizer, declined to testify before the House Judiciary Committee through his lawyer, Susan Brune. Brune informed the committee of this decision on May 29. Jordan subsequently summoned Domitzer, who was scheduled to appear at the committee meeting on July 22 at 10 a.m.

According to a press release, the allegations surrounding Pfizer employees purportedly working to withhold crucial public health information in relation to the 2020 presidential election are significant and merit further investigation. This could lead to potential legislative reforms.

Brune attempted to narrow the document requests from the committee, claiming that her client had no documents that required a response. However, Jordan countered this by suggesting that the response did not adequately address the four categories of information requested.

Brune’s communication seemed to indicate that Pfizer’s representatives would be available to discuss matters, but critics argue that this wasn’t sufficient. The committee had earlier informed Domitzer of evidence hinting that Pfizer executives had communicated with senior law enforcement at GSK multiple times between November 13 and 19, suggesting a deliberate delay in clinical testing to ensure it wouldn’t conclude before the election results were in.

In a tweet, House Judiciary GOP mentioned that the investigation revealed senior Pfizer executives may have colluded to postpone clinical trials for the Covid-19 vaccine, with one executive reportedly so concerned about the inquiry that he considered relocating to Canada.

Furthermore, GSK clarified that the situation did not involve a postponement in revealing completed results but rather a slowdown in the process before disclosure became necessary. Brune’s response didn’t challenge this point, raising more questions about Pfizer’s intentions.

Jordan emphasized that Domitzer’s testimony was crucial for the committee’s oversight, arguing that Brune’s response fell short and did not justify Domitzer’s lack of compliance with the subpoena. He reiterated that while Pfizer might have provided some information, this did not absolve Domitzer’s obligation to testify.

Jordan had previously sent a letter to Domitzer and Pfizer’s CEO, Dr. Albert Bourla, on May 15, demanding answers regarding claims that Pfizer intentionally delayed announcing the results of its final Phase 3 trial and vaccine efficacy until after the election, supposedly to avoid assisting in Trump’s re-election effort.